Literature DB >> 12587101

Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial.

Christopher J Weir1, Kennedy R Lees.   

Abstract

Achieving balance on prognostic factors between treatment groups in a clinical trial is important to ensure that any observed treatment effect may be attributed to the treatment itself. Improving the balance on prognostic factors also potentially increases the statistical power attained in a trial. Substantial imbalances may occur by chance if simple randomization is used. Allocation of the treatment according to stratified random blocks based on clinical features is the conventional approach to obtain treatment groups that are as similar as possible. An alternative approach, known as minimization (or more generally as adaptive stratification), has also been proposed. We assessed the feasibility of adaptive stratification in the context of a clinical trial of insulin to control plasma glucose level following acute stroke. We determined suitable settings for the parameters in the adaptive stratification procedure by simulation studies. Specifically, we assessed: the optimal probability for allocating a patient to the preferred (leading to least imbalance on prognostic factors) treatment group; the number of variables that could be incorporated in the adaptive stratification algorithm; the weighting that should be given to each variable; and whether interactions between variables should be included. We then compared the statistical power, across a range of simulated treatment effects, between trials where treatments were allocated by stratified random blocks and by adaptive stratification. Finally, we considered the importance of the method of analysis in realizing the gain in power which may potentially be achieved by allocating treatments using stratified random blocks or adaptive stratification. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12587101     DOI: 10.1002/sim.1366

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  29 in total

1.  Preventing recurrence of thromboembolic events through coordinated treatment in the District of Columbia.

Authors:  Alexander W Dromerick; Michael C Gibbons; Dorothy F Edwards; Deeonna E Farr; Margot L Giannetti; Brisa Sánchez; Nawar M Shara; Ali Fokar; Annapurni Jayam-Trouth; Bruce Ovbiagele; Chelsea S Kidwell
Journal:  Int J Stroke       Date:  2011-10       Impact factor: 5.266

2.  Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial.

Authors:  Daniel F Hanley; Karen Lane; Nichol McBee; Wendy Ziai; Stanley Tuhrim; Kennedy R Lees; Jesse Dawson; Dheeraj Gandhi; Natalie Ullman; W Andrew Mould; Steven W Mayo; A David Mendelow; Barbara Gregson; Kenneth Butcher; Paul Vespa; David W Wright; Carlos S Kase; J Ricardo Carhuapoma; Penelope M Keyl; Marie Diener-West; John Muschelli; Joshua F Betz; Carol B Thompson; Elizabeth A Sugar; Gayane Yenokyan; Scott Janis; Sayona John; Sagi Harnof; George A Lopez; E Francois Aldrich; Mark R Harrigan; Safdar Ansari; Jack Jallo; Jean-Louis Caron; David LeDoux; Opeolu Adeoye; Mario Zuccarello; Harold P Adams; Michael Rosenblum; Richard E Thompson; Issam A Awad
Journal:  Lancet       Date:  2017-01-10       Impact factor: 79.321

3.  Second-order interactions with the treatment groups in controlled clinical trials.

Authors:  Shyang-Yun Pamela K Shiao; Chul W Ahn; Kouhei Akazawa
Journal:  Comput Methods Programs Biomed       Date:  2007-02-14       Impact factor: 5.428

4.  Issues in outcomes research: an overview of randomization techniques for clinical trials.

Authors:  Minsoo Kang; Brian G Ragan; Jae-Hyeon Park
Journal:  J Athl Train       Date:  2008 Apr-Jun       Impact factor: 2.860

5.  Randomization in clinical trials: stratification or minimization? The HERMES free simulation software.

Authors:  Hélène Fron Chabouis; Francis Chabouis; Florence Gillaizeau; Pierre Durieux; Gilles Chatellier; N Dorin Ruse; Jean-Pierre Attal
Journal:  Clin Oral Investig       Date:  2013-03-01       Impact factor: 3.573

6.  A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III).

Authors:  Wendy C Ziai; Nichol McBee; Karen Lane; Kennedy R Lees; Jesse Dawson; Paul Vespa; Richard E Thompson; A David Mendelow; Carlos S Kase; J Ricardo Carhuapoma; Carol B Thompson; Steven W Mayo; Pat Reilly; Scott Janis; Craig S Anderson; Mark R Harrigan; Paul J Camarata; Jean-Louis Caron; Mario Zuccarello; Issam A Awad; Daniel F Hanley
Journal:  Int J Stroke       Date:  2019-04-03       Impact factor: 5.266

7.  Validity and power of minimization algorithm in longitudinal analysis of clinical trials.

Authors:  Hua Weng; Randall Bateman; John C Morris; Chengjie Xiong
Journal:  Biostat Epidemiol       Date:  2017-06-13

Review 8.  Simpson's paradox and experimental research.

Authors:  Suzanne Ameringer; Ronald C Serlin; Sandra Ward
Journal:  Nurs Res       Date:  2009 Mar-Apr       Impact factor: 2.381

9.  The impact of covariate misclassification using generalized linear regression under covariate-adaptive randomization.

Authors:  Liqiong Fan; Sharon D Yeatts; Bethany J Wolf; Leslie A McClure; Magdy Selim; Yuko Y Palesch
Journal:  Stat Methods Med Res       Date:  2015-11-23       Impact factor: 3.021

10.  Participation of a coordinating center pharmacy in a multicenter international study.

Authors:  Jihyun Esther Jeon; Janet Mighty; Karen Lane; Nichol McBee; Ryan Majkowski; Steven Mayo; Daniel Hanley
Journal:  Am J Health Syst Pharm       Date:  2016-11-15       Impact factor: 2.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.